Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 79 for “"Proteolysis Targeting Chimeras"”.

  1. Novel glycomimetic inhibitors and proteolysis-targeting chimeras for human galectins

    … we designed and synthesized two proteolysis-targeting chimeras (PROTACs) for human galectins to investigate whether galectins are amenable to targeted protein degradation. Although both compounds displayed nanomolar affinities for galectin-3, they failed to induce galectin-3 …

    lund Repository record for Novel glycomimetic inhibitors and proteolysis-targeting chimeras for human galectins (opens in a new tab) Download PDF for Novel glycomimetic inhibitors and proteolysis-targeting chimeras for human galectins (opens in a new tab)

  2. Development of Proteolysis Targeting Chimeras Prodrugs Targeting Cancer and Senescence

    Proteolysis targeting chimeras (PROTACs) is an emerging therapeutic modality that recruits the cell’s ubiquitin-proteasome system to degrade the target protein by bringing the protein and an E3 ligase together. The technology has been demonstrated in the treatment of various disorders, including …

    arizona-thes Repository record for Development of Proteolysis Targeting Chimeras Prodrugs Targeting Cancer and Senescence (opens in a new tab)

  3. Induced Degradation of G-Protein-Coupled Receptors Through Proteolysis Targeting Chimeras

    … roles in cancer progression. TPD methods include proteolysis targeting chimeras (PROTACs), which are heterobifunctional molecules where one end has a ligand for the protein-of-interest (POI), and the other end has an E3 ligase recruiting ligand. PROTACs take advantage of the ubiquitin-proteasome …

    rockefeller Repository record for Induced Degradation of G-Protein-Coupled Receptors Through Proteolysis Targeting Chimeras (opens in a new tab)

  4. Investigations of the synthesis and properties of romodomain and extra-terminal domain proteolysis targeting chimeras

    Hijacking a cell’s ubiquitin proteasome system using PROTAC technology has the potential to be a powerful new therapeutic strategy. Some of the main advantages of this technology include the potential for PROTACs to be catalytic in activity and elicit long-lasting therapeutic effects, offering the …

    strathclyde Repository record for Investigations of the synthesis and properties of romodomain and extra-terminal domain proteolysis targeting chimeras (opens in a new tab)

  5. Advanced Mesoporous Particles for Colon-targeted Delivery: Insights into Enhanced Delivery of Proteolysis-targeting Chimeras

    Proteolysis-targeting Chimeras (PROTACs) are revolutionary molecules that induce target protein degradation and, therefore, are suited for intractable drug targets. However, they challenge traditional delivery methods for small molecules via the oral route due to their complex physiochemical …

    aston Repository record for Advanced Mesoporous Particles for Colon-targeted Delivery: Insights into Enhanced Delivery of Proteolysis-targeting Chimeras (opens in a new tab) Download PDF for Advanced Mesoporous Particles for Colon-targeted Delivery: Insights into Enhanced Delivery of Proteolysis-targeting Chimeras (opens in a new tab)

  6. Proteolysis Targeting Chimeras (PROTACs) for the Degradation of the Epigenetic Regulators CBP/EP300 and BAZ2A/BAZ2B

    Proteolysis Targeting Chimeras (PROTACs) are a novel class of bifunctional small molecules that trigger protein degradation by hijacking the cellular proteolysis machinery, i.e., the ubiquitin-proteasome System (UPS). These bifunctional probes typically consist of a ligand for the protein of …

    zurich

  7. Proteolysis Targeting Chimeras: proteasomal degradation of platelet BTK and TEC as a novel approach in thrombosis prevention

    … recently developed small molecule degraders (PROteolysis TArgeting Chimeras, PROTACs) that utilise the proteasomal system to degrade BTK. Human platelet rich plasma (PRP) was treated with various concentrations of PROTACs and were subjected to immunoblotting and assessed for integrin αIIbβ₃ …

    bristol Repository record for Proteolysis Targeting Chimeras: proteasomal degradation of platelet BTK and TEC as a novel approach in thrombosis prevention (opens in a new tab) Download PDF for Proteolysis Targeting Chimeras: proteasomal degradation of platelet BTK and TEC as a novel approach in thrombosis prevention (opens in a new tab)

  8. Development of Hoveyda-Grubbs-Type Precatalysts and Isocyanide-Based Metal Scavengers and Their Applications in the Synthesis of Pharmacologically-Relevant Molecules

    … study, olefin metathesis was used to prepared proteolysis-targeting chimeras. Two different E3 ubiquitin ligases were targeted for the degradation of HER-2 tyrosine kinase. The synthesis of alkene-containing protein ligands, subsequent olefin cross-metathesis, and alkene reduction afforded a …

    buffalo Repository record for Development of Hoveyda-Grubbs-Type Precatalysts and Isocyanide-Based Metal Scavengers and Their Applications in the Synthesis of Pharmacologically-Relevant Molecules (opens in a new tab)

  9. Machine Learning for PROTAC Decomposition and Enhanced Degradation Prediction

    PROTACs (Proteolysis Targeting Chimeras) are bifunctional molecules composed of three components that mediate the degradation of target proteins, and are widely used in drug discovery. This project explores the application of machine learning in two key aspects: splitting PROTAC molecules into …

    chalmers Repository record for Machine Learning for PROTAC Decomposition and Enhanced Degradation Prediction (opens in a new tab)

  10. Targeted protein degradation of the Y220C-p53 mutant as a potential anti-cancer strategy

    Targeted protein degradation and Proteolysis Targeting Chimeras (PROTACs) in particular, have become an exciting new field in the drug discovery world, with the potential to target previously seen as ‘undruggable’ proteins. With many PROTACs now reaching the clinic, it is clear that these new …

    glasgow Repository record for Targeted protein degradation of the Y220C-p53 mutant as a potential anti-cancer strategy (opens in a new tab) Download PDF for Targeted protein degradation of the Y220C-p53 mutant as a potential anti-cancer strategy (opens in a new tab)

  11. Modulation of Receptor Tyrosine Kinases Using Ubiquitin Variant Induced Proximity

    … and protein research. Degradation occurs through proteolysis targeting chimeras, which recruit ubiquitin ligase proteins (E3 ligase) to a target protein to facilitate ubiquitination. By contrast, stabilization occurs through deubiquitinase targeting chimeras, which remove ubiquitin moieties. These …

    guelph Repository record for Modulation of Receptor Tyrosine Kinases Using Ubiquitin Variant Induced Proximity (opens in a new tab)

  12. Σχεδιασμός και σύνθεση αναστολέων των κινασών MARK

    … indolocarbazoles, b) acridone derivatives and c) proteolysis targeting chimeras bearing acridone. In the first part of the present thesis, bisindole pyrroles and indolocarbazoles were designed as potential MARK4 inhibitors. Both structures and the designed synthetic route were inspired by the …

    greece Repository record for Σχεδιασμός και σύνθεση αναστολέων των κινασών MARK (opens in a new tab)

  13. PROTACs – A Novel and Rapidly Developing Field of Targeted Protein Degradation

    … the realm of targeted protein degradation called Proteolysis-Targeting Chimeras (PROTACs). This technology specifically targets and degrades disease-causing proteins via the ubiquitin-proteasome system, and has seen an explosion of research and intrigue in both academia and industry over the past …

    vcu Repository record for PROTACs – A Novel and Rapidly Developing Field of Targeted Protein Degradation (opens in a new tab)

  14. Discovery of DYR684, a First-in-Class DYRK1A/B PROTAC

    … Here we report the development of DYRK1 proteolysis targeting chimeras (PROTACs) that combine a new ATP-competitive DYRK1 inhibitor with ligands for the E3 ubiquitin ligase component Cereblon (CRBN) to induce ubiquitination and subsequent proteasomal degradation of DYRK1A and DYRK1B. The …

    arizona-thes Repository record for Discovery of DYR684, a First-in-Class DYRK1A/B PROTAC (opens in a new tab)

  15. Σχεδιασμός και Ανάπτυξη νέων PROTACs έναντι της P38α κινάσης

    … στην πρωτεΐνη P38α. Η τεχνολογία των PROTACs (PROteolysis TArgeting Chimeras) προσφέρει μια καινοτόμο στρατηγική φαρμακευτικής παρέμβασης, επιτρέποντας την επιλεκτική αποδόμηση πρωτεϊνών μέσω της χρήσης του συστήματος ουβικιτίνης-πρωτεασώματος. Είναι σύνθετα μόρια που αποτελούνται από τρία …

    athens Repository record for Σχεδιασμός και Ανάπτυξη νέων PROTACs έναντι της P38α κινάσης (opens in a new tab)

  16. Branched peptide-based targeted protein degraders for the modulation of ternary complex geometry

    Proteolysis Targeting Chimeras (PROTACs) are heterobifunctional targeted protein degraders that selectively degrade a protein of interest (POI) by recruiting innate protein degradation machinery. The current PROTAC design landscape is limited by the use of small molecules as ligands which are …

    cornell Repository record for Branched peptide-based targeted protein degraders for the modulation of ternary complex geometry (opens in a new tab)

  17. Exploring linker fluorination to optimise PROTAC potency, selectivity, and physical properties

    PROteolysis TArgeting Chimeras (PROTACs) have emerged as an exciting new modality in drug discovery for catalytically inducing targeted protein degradation. They consist of protein binding ligands for an E3 ubiquitin ligase and the protein to be degraded joined together by a linker, the length and …

    soton Download PDF for Exploring linker fluorination to optimise PROTAC potency, selectivity, and physical properties (opens in a new tab)

Page 1 of 4